Outcome Measures
schizophrenia, first-episode schizophrenia
SECONDARY, REMISSION
The primary efficacy outcome of this trial was the percentage PANSS score change from baseline to the end of week 6. Percentage PANSS score change was calculated using the difference between the baseline and follow-up scores divided by the baseline score minus 30.The secondary outcome was response or remission rates at each time point. Early response was defined as a percentage PANSS score change of 20% or more at the end of week 2,There were several exploratory outcome measurements. Patients in the MPGT group were divided into subgroups of patients with first-episode schizophrenia and relapsed schizophrenia to compare their therapeutic efficacy. We also evaluate the distribution of pharmacogenomic recommendation levels in the TAU group and compared the differences in treatment efficacy among the recommendation levels. The dose of medications and metabolic profile, including triglyceride, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose (FPG), and prolactin, were evaluated.